Navigation Links
Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
Date:10/9/2008

Proceeds to be used to support the achievement of several value-creating

developments and commercial milestones of Acasti Pharma

LAVAL, QC, Oct. 9 /PRNewswire-FirstCall/ - The Board of Directors of Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced that the Company successfully completed as of October 8, 2008, the private placement of units of convertible debentures for gross proceeds of $2,750,000.

The convertible debentures bear interest at the rate of 8% per year and mature three years from issuance. Upon maturity, the convertible debentures may be redeemed by Neptune in cash or converted, with a premium, into Neptune common shares. The proceeds from this financing will be invested by Neptune into Acasti Pharma in order to reach several value-creating development and commercial milestones within Acasti Pharma's over-the-counter, prescription medical food and prescription drug programs. The Board of Directors' decision to proceed with the private placement up to a maximum of $2,750,000 was influenced by its desire to provide for minimum dilution while allowing Acasti Pharma to reach critical milestones during the next two years, which is expected to create substantial value for all shareholders.

Each unit of the private placement is comprised of a $1,000 convertible debenture, 400 warrants to acquire shares of Neptune at $1.25 per share and 400 call options allowing the holder to acquire from Neptune an equal number of Acasti Pharma Class A shares, priced at $0.25 per share, in each case expiring on April 30, 2010.

During a period of two years from the date of issuance, the debentures may be converted into units, each comprised of one Neptune common share priced at $1.25 for the principal portion of the convertible debenture and at market price of Neptune common shares for the accrued interest and one-half warrant exercisable at market price. During the time period from June 1,
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... company, announced today the appointment of Adam ... (COO). Cypher Genomics provides rapid and comprehensive annotation ... discovery and clinical reporting. "Cypher,s technology ... to improve healthcare by enhancing diagnostic accuracy, optimizing ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... 22, 2011 Qteros, Inc., the developer of a ... platform for the lowest-cost production of cellulosic ethanol, today ... in June. Susan Hager, Qteros, Vice President ... the 2011 BIO International Convention at the Walter E. ...
... 21, 2011 ,   ... of Matthew Roe as Chief Business Officer. Matthew ... Director,Business Development & Licensing. During a ... alliance management, acquisition, divestment, and sales,and marketing, and ...
... physics there are two classes of fundamental particles. Photons, ... and neutrons that make up atomic nuclei belong to ... at a very basic level. This difference is expressed ... species of fundamental particle was postulated, which was dubbed ...
Cached Biology Technology:Qteros Management to Speak at June Conferences 2Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2Acrobatics for anyons: New test for elusive fundamental particle proposed 2
(Date:7/24/2014)... multi-institutional team of researchers has developed a new nanoscale ... noninvasive method for assessing the function and properties of ... better diagnosis and treatment of gut diseases. ... bowel syndrome and inflammatory bowel disease all occur in ... in patients with diseases such as diabetes and Parkinson,s. ...
(Date:7/24/2014)... at The University of Texas Health Science Center at ... to help Harris County residents whose vision problems cannot ... with corrective lenses, many people with low vision can ... of low vision devices, such as telescopes, magnifiers and ... Iyer is using the three-year, $164,645 SightFirst grant from ...
(Date:7/24/2014)... cleanup experts gathered at NJIT this week for an ... the U.S. Environmental Protection Agency (EPA) to dredge toxic ... River. , The EPA has called the plan, which ... and capping sections of the riverbed, one of the ... would be dredged and disposed off-site. , "We need ...
Breaking Biology News(10 mins):New imaging agent provides better picture of the gut 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... Boston University School of Medicine (BUSM) demonstrates a new mechanism ... the formation of new blood vessels and cancer growth. The ... Signaling . Angiogenesis creates new blood vessels in a ... several diseases such as cancer and age-related macular degeneration. ...
... A new study published in the December issue of ... only in terms of its impact on current coastal conditions ... past. Hurricane Irene made landfall in Onslow Bay, North Carolina, ... been downgraded to a Category 1 hurricane after hitting the ...
... Do fruit flies hold the key to treating dementia? ... a significant step forward in unraveling the mechanisms of ... memories form and, ultimately, provide better treatments to improve ... associate professor of biology and biochemistry at UH, and ...
Cached Biology News:New clues to memory formation may help better treat dementia 2New clues to memory formation may help better treat dementia 3
Red Standard is sodium salt of resorufin....
APG5 autophagy 5-like (S. cerevisiae)...
...
Griess Reagent component for determination of nitrite in aqueous solutions....
Biology Products: